CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

• Market Cap: $9.46M
• Dividend Yield: N/A
• Average Volume (3M): 166.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.15
• Revenue Growth: N/A
• EPS Growth: -21.99%
• Country: US
• Employees: 43
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 11,733,712
• 10 Day Avg. Volume: 104,297
• 30 Day Avg. Volume: 166,789
• PEG Ratio: 0.46
• Price to Book (P/B): 5.98
• Price to Sales (P/S): 754.46
• P/FCF Ratio: -13.04
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 20.73
• Enterprise Value/Gross Profit: 19.98
• Enterprise Value/Ebitda: -2.97
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.85 ▼(-38.56% Downside)

The score is driven primarily by weak financial performance (sharp revenue decline, sizable net losses, and negative free cash flow), reinforced by bearish technicals (price below major moving averages and negative MACD). Valuation is not supportive because the negative P/E reflects ongoing losses and there is no dividend yield data.

Positive Factors

Platform expansion via acquisition

The TCB-002 acquisition broadens CytoMed's non‑viral allogeneic gamma delta T‑cell platform, adds an asset with Phase I data and FDA orphan designation, and accelerates entry into China/India regulatory pathways, improving long‑term product and market optionality.

Clinical partnerships and trial footprint

The Universiti Malaya MOU expands CytoMed's Southeast Asia clinical footprint and enables a multi‑site Phase I program, which supports regulatory filings, enhances patient recruitment and data robustness, and de‑risks clinical development for future licensing or partnerships.

Near-term runway and non-dilutive funding

Reporting at least a year of resources plus a non‑dilutive investment for LongevityBank reduces immediate financing pressure, allowing focus on clinical milestones, strategic licensing and monetisation options with less near‑term dilution risk while development proceeds.

Negative Factors

Revenue collapse

A dramatic decline in revenue signals weak commercialization or demand and undermines internal funding capacity for R&D and operations. Persistent low revenue increases reliance on external capital and raises execution and survival risk over the medium term.

Sustained net losses and negative free cash flow

Large net losses and a substantial FCF deficit indicate structural cash burn. Continued negative cash generation compels repeat fundraising or asset monetisation, which can dilute shareholders or delay programs if capital markets tighten, impairing long‑term execution.

Shrinking balance sheet buffers

Declines in assets and equity reduce the company's financial resilience despite low debt. A weakened equity buffer limits capacity to absorb clinical or operational setbacks, constrains borrowing options and increases the likelihood of dilutive financings if cash burn persists.

CytoMed Therapeutics Limited Business Overview & Revenue Model

Company Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

How the Company Makes Money

CytoMed Therapeutics generates revenue through multiple streams, including the commercialization of its proprietary therapies and technologies, licensing agreements with pharmaceutical companies, and partnerships with research institutions. The company may receive upfront payments, milestone payments based on the progress of clinical trials, and royalties on sales from licensed products. Additionally, funding from government grants and collaborations with industry partners contribute to its financial stability. Significant partnerships with key players in the biotech industry also enhance its research capabilities and market reach, thereby driving further revenue growth.

CytoMed Therapeutics Limited Financial Statement Overview

Summary

Financials are weak: revenue fell sharply from $290,560 (2023) to $52,005 (2024), net loss remained large at -$1,883,178 (2024), and operating/free cash flow were negative (FCF -$2,742,350). The main offset is a relatively strong equity position versus debt, though total assets and equity declined year over year.

Income Statement

The income statement reveals significant challenges, with the company experiencing a decline in total revenue from $290,560 in 2023 to $52,005 in 2024, indicating a negative revenue growth rate. Additionally, the net income remained negative, with a considerable net loss of $1,883,178 in 2024, reflecting poor profitability and a concerning net profit margin.

Balance Sheet

The balance sheet shows a strong equity position with stockholders' equity significantly outweighing total debt, resulting in a low debt-to-equity ratio. However, the reduction in total assets and stockholders' equity from 2023 to 2024 highlights potential risks and financial instability.

Cash Flow

The cash flow statement indicates negative operating cash flow, with a substantial free cash flow deficit of $2,742,350 in 2024. While the company had a significant capital expenditure in 2024, the free cash flow remains negative, pointing to cash management challenges and the need for more efficient cash utilization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	366.78K	52.01K	290.56K	0.00	84.18K	44.92K
Gross Profit	380.54K	52.38K	381.92K	-81.03K	81.59K	41.43K
EBITDA	-2.56M	-1.79M	-2.94M	-1.10M	-1.05M	-776.21K
Net Income	-3.35M	-1.88M	-3.13M	-2.27M	-1.53M	-1.47M
Balance Sheet
Total Assets	6.57M	7.37M	9.37M	3.90M	4.51M	2.89M
Cash, Cash Equivalents and Short-Term Investments	2.25M	3.64M	6.82M	1.18M	1.87M	703.20K
Total Debt	385.05K	339.20K	339.50K	3.15M	2.42M	2.26M
Total Liabilities	892.51K	749.76K	852.28K	3.46M	2.59M	2.53M
Stockholders Equity	5.62M	6.57M	8.52M	438.24K	1.92M	360.37K
Cash Flow
Free Cash Flow	-3.03M	-3.01M	-2.72M	-1.40M	-1.70M	-828.43K
Operating Cash Flow	-2.40M	-1.98M	-2.68M	-1.04M	-1.27M	-643.14K
Investing Cash Flow	2.79M	494.59K	-2.11M	-353.37K	-610.72K	-371.94K
Financing Cash Flow	-64.25K	-33.36K	8.16M	793.25K	3.09M	1.44M

CytoMed Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Negative. The current price of 1.39 is above the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.42, and below the 200-day MA of 1.93, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 31.44 is Neutral, neither overbought nor oversold. The STOCH value of 27.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDTC.

CytoMed Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PASG	49 Neutral	$35.88M	-0.83	-87.18%	―	―	38.42%
MTVA	46 Neutral	$8.06M	-0.15	-168.18%	―	―	71.57%
GDTC	42 Neutral	$9.46M	-3.58	-42.29%	―	―	-21.99%
AKTX	42 Neutral	$7.65M	―	-196.60%	―	―	―

CytoMed Therapeutics Limited Corporate Events

CytoMed Therapeutics Refutes Misleading Claims, Confirms Ongoing First-in-Human Trial

On January 28, 2026, CytoMed Therapeutics issued a statement refuting what it described as inaccurate and misleading public claims about its research programs, clinical progress and operations, asserting that some of these assertions were taken out of context and aimed at influencing its share price. The company clarified that its core research centers on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, confirmed that its lead CAR γδ T cell program has regulatory approval and is already in a first-in-human clinical trial at Singapore’s National University Hospital, and emphasized that its other candidates remain in preclinical stages and are not approved for commercial use, underscoring its commitment to regulatory compliance, scientific rigor, transparent disclosure and potential action against dissemination of false information affecting its stakeholders.

The most recent analyst rating on (GDTC) stock is a Hold with a $0.85 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.

CytoMed Therapeutics Outlines 2026 Clinical Plans and Seeks Shareholder Input on Patient-Access Scheme

On January 13, 2026, CytoMed Therapeutics issued a New Year update outlining its operational progress, financial runway, and strategic initiatives, including diversification into cord blood-derived natural killer cell therapies through its LongevityBank subsidiary and ongoing support from Enterprise Singapore. The company reported it has sufficient resources to fund activities for at least a year, is exploring licensing, real estate monetisation and strategic partnerships to strengthen its business with limited dilution, and noted that Chairman Peter Choo intends to increase his shareholding. CytoMed highlighted a December 8, 2025 memorandum of understanding with Universiti Malaya to launch a multi-site first-in-human Phase I trial in Malaysia of its allogeneic unmodified gamma delta T cells (CTM-GDT) for no-option cancer patients, targeting an investigational new drug submission before June 2026, which complements its ongoing Phase I CAR-T γδ T cell trial (CTM-N2D) at National University Hospital Singapore where six patients have been treated. The company also underscored recent preclinical data co-published with MD Anderson Cancer Center in September/October 2025 supporting the potential of its CTM-GDT therapy in acute myeloid leukemia, reinforcing its positioning in off-the-shelf cell therapies. In a notable move aimed at aligning with long-term investors, CytoMed said it plans to seek shareholder feedback on a proposed scheme that would allow shareholders, subject to medical approval and local regulations, to use their shareholdings to gain access to its donor-derived allogeneic unmodified gamma delta T cell treatments, potentially reshaping how patient capital is rewarded and further cementing its Southeast Asia-based, cost-efficient medical tourism proposition in oncology.

The most recent analyst rating on (GDTC) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.

CytoMed Therapeutics Partners with Malaysian Hospital for Groundbreaking Cancer Trial

On December 8, 2025, CytoMed Therapeutics Limited announced a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia to establish a multi-site, first-in-human Phase I clinical trial for its patented donor-derived gamma delta T cell product candidate. This trial aims to evaluate the safety and efficacy of these cells in cancer patients who have exhausted standard treatments. This collaboration is expected to provide an affordable immunotherapy option for patients with limited treatment alternatives, leveraging the natural ability of T cells to detect and kill cancer cells. The initiative complements CytoMed’s ongoing trials in Singapore and reflects its commitment to advancing clinical innovation in Southeast Asia.

The most recent analyst rating on (GDTC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.

CytoMed Therapeutics Finalizes Acquisition of T Cell Technology for Cancer Treatment in China and India

On November 18, 2025, CytoMed Therapeutics Limited announced the completion of its acquisition of TC BioPharm Limited’s gamma delta T cell technology, TCB-002, to enhance cancer treatment capabilities in China and India. This acquisition aligns with CytoMed’s strategy to establish a non-viral allogeneic gamma delta T cell immunotherapy platform. The technology, which has completed a Phase I clinical trial in Europe and received orphan drug designation by the FDA for Acute Myeloid Leukemia, will be adapted for use in China and India, leveraging new regulatory pathways and cost-effective manufacturing processes. This move replaces previous agreements with Chinese parties and positions CytoMed to capitalize on recent regulatory changes in China, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (GDTC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.

CytoMed Therapeutics Secures Investment and Advances China Strategy

On November 6, 2025, CytoMed Therapeutics announced securing a non-dilutive investment from ICH Capital for its subsidiary LongevityBank, which focuses on autologous therapies. The investment will help LongevityBank expand its personalized cellular banking services. Additionally, CytoMed is exploring a new strategy in China, leveraging recent regulatory changes to introduce its allogeneic gamma delta T cell platform. This strategic move is expected to enhance CytoMed’s market positioning in Southeast Asia and China, potentially benefiting stakeholders by expanding treatment options and improving accessibility to innovative cancer therapies.

The most recent analyst rating on (GDTC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.